Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,487 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Detection of multiple druggable mutations of lung cancer from cytology specimens by MINtS: An advanced medicine A trial.
Fujita K, Arai R, Shoji S, Saito R, Nomura M, Hotta T, Asahina H, Kawakami M, Nakachi I, Hasegawa Y, Okafuji K, Suzuki A, Miyanaga A, Sunaga N, Nagashima H, Ikeda N, Watanabe S, Nagai Y, Furuta M, Kage H, Arai D, Fukuhara T, Nakayama M, Morita S, Kobayashi K, Hagiwara K. Fujita K, et al. Among authors: morita s. Cancer Sci. 2023 Aug;114(8):3342-3351. doi: 10.1111/cas.15831. Epub 2023 May 3. Cancer Sci. 2023. PMID: 37139543 Free PMC article.
A Phase I/II Study of Necitumumab Plus Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small Cell Lung Cancer Study: (NEJ048A/NEXUS).
Miyanaga A, Asahina H, Watanabe S, Shukuya T, Tsubata Y, Hosomi Y, Sugawara S, Maemondo M, Okano T, Morita S, Matsuyama K, Kobayashi K, Seike M. Miyanaga A, et al. Among authors: morita s. Clin Lung Cancer. 2023 Jun;24(4):371-375. doi: 10.1016/j.cllc.2023.01.008. Epub 2023 Feb 1. Clin Lung Cancer. 2023. PMID: 36849264 Free article. Clinical Trial.
Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312).
Katakami N, Nishimura T, Hidaka Y, Hata A, Nishino K, Mori M, Hirashima T, Takase N, Kaneda T, Ohnishi H, Morita S, Hatachi Y. Katakami N, et al. Among authors: morita s. Lung Cancer. 2023 Aug;182:107261. doi: 10.1016/j.lungcan.2023.107261. Epub 2023 May 26. Lung Cancer. 2023. PMID: 37307753 Clinical Trial.
Dynamic tumor-tracking stereotactic body radiotherapy with real-time monitoring of liver tumors using a gimbal-mounted linac: A multi-institutional phase II study.
Iizuka Y, Hiraoka M, Kokubo M, Sakamoto T, Karasawa K, Murofushi K, Nakamura M, Matsuo Y, Morita S, Inokuchi H, Mizowaki T. Iizuka Y, et al. Among authors: morita s. Clin Transl Radiat Oncol. 2023 Feb 10;39:100591. doi: 10.1016/j.ctro.2023.100591. eCollection 2023 Mar. Clin Transl Radiat Oncol. 2023. PMID: 36852258 Free PMC article.
Clinical Implications and Risk Factors of Dilatation of Remnant Pancreatic Duct at 1 Year After Pancreatoduodenectomy: A Prospective, Japanese, Multicenter, Observational Cohort Study (DAIMONJI-Study).
Narita M, Hatano E, Kitamura K, Terajima H, Kitagawa H, Mitsuoka E, Machimoto T, Morita S, Nishitai R, Masui T; Kyoto University Hepato-Biliary-Pancreatic Surgery (KUHBPS) Group. Narita M, et al. Among authors: morita s. J Am Coll Surg. 2024 May 30. doi: 10.1097/XCS.0000000000001121. Online ahead of print. J Am Coll Surg. 2024. PMID: 38813957
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks).
Takano T, Masuda N, Ito M, Inoue K, Tanabe Y, Kawaguchi K, Yasojima H, Bando H, Nakamura R, Yamanaka T, Ishida K, Aruga T, Yanagita Y, Tokunaga E, Aogi K, Ohno S, Kasai H, Kataoka TR, Morita S, Toi M. Takano T, et al. Among authors: morita s. Breast Cancer Res Treat. 2024 May 20. doi: 10.1007/s10549-024-07333-7. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 38767786
3,487 results